Key Takeaways
- • Apollo Global Management is in non-binding discussions to acquire Johnson & Johnson's DePuy Synthes orthopedics unit for approximately $20 billion, with potential agreement within several weeks, though talks remain preliminary and other bidders may emerge.
- • DePuy Synthes generated $9.3 billion in sales in 2025, representing less than 10% of J&J's total revenue; J&J originally acquired Synthes in 2012 for $21 billion and has signaled willingness to explore multiple separation options for the business.
- • The proposed transaction would divest J&J of its hip and knee devices portfolio, including flagship products such as the ATTUNE Knee System, ACTIS Total Hip System, and CORAIL Total Hip System.
- • Puig Brands has agreed to acquire Esteve's remaining 50% stake in ISDIN for $1.41 billion, consolidating full ownership of the dermatology business.
- • J&J stated at the Wells Fargo Healthcare Conference on September 9 that it is "optimizing for value creation" in any separation of its orthopedics business and remains open to multiple strategic alternatives.
Summary
Johnson & Johnson is advancing discussions with private equity firm Apollo Global Management to divest its DePuy Synthes orthopedics business in a transaction valued near $20 billion. According to Bloomberg sources, the parties are currently in non-binding preliminary talks, with potential agreement possible within several weeks, though negotiations remain fluid and could conclude without a deal or attract competing bidders. J&J first acquired Synthes, then a bone-repair device manufacturer, in 2012 for $21 billion, subsequently creating DePuy Synthes as its comprehensive orthopedics platform.
The DePuy Synthes unit represents a strategically non-core asset for J&J despite its significant scale. In 2025, the business generated $9.3 billion in revenue, accounting for less than 10% of the conglomerate's overall sales. The portfolio encompasses core hip and knee replacement systems including the ATTUNE Knee System, ACTIS Total Hip System, and CORAIL Total Hip System. J&J confirmed its separation intentions publicly during the Wells Fargo Healthcare Conference on September 9, with executives emphasizing that the company is "optimizing for value creation" and remains prepared to consider "a multitude of options" for the orthopedics business separation.
The potential sale to Apollo would represent a significant recapitalization event within the orthopedics medtech sector. However, J&J's openness to multiple separation pathways—including spin-off, partial sale, or full divestiture—suggests the company is conducting a comprehensive strategic review. The preliminary nature of talks with Apollo indicates that the valuation and structure remain subject to negotiation, and alternative buyers may emerge if J&J formally markets the business.
Separately, Puig Brands has agreed to acquire Esteve's 50% remaining stake in ISDIN for $1.41 billion, consolidating full ownership of the dermatology platform. This transaction represents a parallel corporate restructuring within the health and beauty sector.
The DePuy Synthes unit represents a strategically non-core asset for J&J despite its significant scale. In 2025, the business generated $9.3 billion in revenue, accounting for less than 10% of the conglomerate's overall sales. The portfolio encompasses core hip and knee replacement systems including the ATTUNE Knee System, ACTIS Total Hip System, and CORAIL Total Hip System. J&J confirmed its separation intentions publicly during the Wells Fargo Healthcare Conference on September 9, with executives emphasizing that the company is "optimizing for value creation" and remains prepared to consider "a multitude of options" for the orthopedics business separation.
The potential sale to Apollo would represent a significant recapitalization event within the orthopedics medtech sector. However, J&J's openness to multiple separation pathways—including spin-off, partial sale, or full divestiture—suggests the company is conducting a comprehensive strategic review. The preliminary nature of talks with Apollo indicates that the valuation and structure remain subject to negotiation, and alternative buyers may emerge if J&J formally markets the business.
Separately, Puig Brands has agreed to acquire Esteve's 50% remaining stake in ISDIN for $1.41 billion, consolidating full ownership of the dermatology platform. This transaction represents a parallel corporate restructuring within the health and beauty sector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.